Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service incontinence, prolapse & sacral neuromodulation cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 31 | 2,524 | 45% |
| 2020 | 20 | 1,816 | 51% |
| 2021 | 23 | 1,912 | 55% |
| 2022 | 25 | 1,864 | 59% |
| 2023 | 23 | 1,905 | 63% |
| 2024 | 25 | 1,789 | 66% |
| 2025 from claims | – | 1,523 1,397–1,611 | 67% |
| 2026 forecast | – | 1,529 1,345–1,764 | 67% |
| 2027 forecast | – | 1,518 1,298–1,809 | 68% |
| 2028 forecast | – | 1,507 1,257–1,845 | 69% |
| 2029 forecast | – | 1,495 1,221–1,875 | 70% |
| 2030 forecast | – | 1,482 1,187–1,899 | 70% |
Slings, artificial sphincter, colpopexy, sacral neuromodulation, penile prosthesis. Professional codes (what the surgeon bills): CPT 57288, 53440, 53445, 57425, 57282, 57283, 64581, 64590, 54405.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 68% of the cases CMS names in Michigan; 16 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 2% inpatient hospital, 94% hospital outpatient, 4% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 37 | 2,896−3.5%/yr | −3.5%/yr | 2.6 | 7% | 2,970 in 2030+0.4%/yr |
| Illinois | 39 | 2,574−0.2%/yr | −0.2%/yr | 1.9 | 8% | 3,390 in 2030+4.7%/yr |
| Indiana | 18 | 1,755−4.5%/yr | −4.5%/yr | 2.5 | 16% | 1,650 in 2030−1%/yr |
| Missouri | 21 | 1,596−2.3%/yr | −2.3%/yr | 2.6 | 10% | 1,480 in 2030−1.2%/yr |
| Minnesota | 16 | 1,110+0.9%/yr | +0.9%/yr | 2.4 | 7% | 1,930 in 2030+9.7%/yr |
| Wisconsin | 13 | 1,066+0.3%/yr | +0.3%/yr | 1.9 | 3% | 1,370 in 2030+4.2%/yr |
| Kansas | 15 | 1,028−2.4%/yr | −2.4%/yr | 2.5 | 21% | 990 in 2030−0.6%/yr |
| Nebraska | 12 | 849−2%/yr | −2%/yr | 3.2 | 24% | 1,020 in 2030+3.1%/yr |
| Iowa | 7 | 604−0.6%/yr | −0.6%/yr | 1.4 | 14% | 600 in 2030−0.1%/yr |
| South Dakota | 4 | 4160%/yr | 0%/yr | 3.2 | 0% | 540 in 2030+4.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 94 | 4,688−5.4%/yr | −5.4%/yr | 5.61.0× | 6% | 4,480 in 2030−0.8%/yr |
| BPH procedures | 40 | 3,700−3.6%/yr | −3.6%/yr | 4.30.9× | 29% | 3,320 in 2030−1.8%/yr |
| Hysterectomy, hysteroscopy & ablation | 15 | 2,577−6%/yr | −6%/yr | 3.41.2× | 11% | 2,550 in 2030−0.1%/yr |
| Prostatectomy & nephrectomy | 10 | 897−4.5%/yr | −4.5%/yr | 1.20.8× | 0% | 1,150 in 2030+4.2%/yr |
Incontinence, prolapse & sacral neuromodulation in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Ohio
Medtronic leads with 42% of company spending on these surgeons in 2025, +13 pts on 2024.
In 2025, 9 companies reported engagement with Michigan’s surgeons worth $320K in consulting, speaking, meals and travel tied to these products, about $13K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.